Amgen and AstraZeneca unveiled their first, direct-to-consumer U.S. advertising campaign in severe asthma called “Be You.” Launching ahead of Asthma & Allergy Awareness Month in May, the “Be You” campaign leverages visually distinct animated characters who do not let their disease define them. The campaign aims to raise awareness about a new severe asthma medicine called TEZSPIRE (tezepelumab-ekko).
Apotex Corp. announced April 12 the company’s release of Paclitaxel protein-bound particles for injection (albumin-bound), a generic version of Abraxane in the United States.
Boehringer Ingelheim announced the company’s intention to pump €25 billion ($27 billion) into its R&D pipeline over the next five years.
The U.S. Food and Drug Administration approved BioXcel Therapeutics Inc.’s IGALMI (dexmedetomidine) sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
The Digital Medicine Society (DiMe), in partnership with Anthem, Biogen, Eli Lilly, Evidation, Janssen, Merck, Pfizer and Savvy Co-op, announced the public launch of the 3Ps of Digital Endpoint Value (3Ps), a toolkit of resources created to facilitate the inclusion of digital endpoints as evidence for payers in reimbursement decisions for new drugs.
Lumanity announced the acquisition of Innovative Edge (IE), a leading provider of pharmaceutical product launch services. IE partners with world-leading biopharma companies – from Top 20 pharmaceutical manufacturers to fast-growing biotechnology companies – to optimize and accelerate their global, regional, and local product launches.
The Biden administration on Wednesday launched a new website to provide a clearinghouse of information on COVID-19 as part of a continuing effort to prepare Americans to live with the coronavirus.
MyAdvice, a leading provider of software-based marketing solutions for medical, dental and law practices, announced the addition of new functionality to its industry-leading Catalyst website.
EVERSANA, a pioneer of next generation commercial services to the global life sciences industry, unveiled NAVLIN by EVERSANA™, a new, comprehensive ecosystem of price and access solutions to help established and emerging pharmaceutical companies navigate global market access complexities. NAVLIN combines best-in-class data, software and insights into an integrated platform, backed by a team of innovative industry experts.
IQVIA announced the launch of OCE+, the first of several new advancements to its leading life science customer engagement platform. OCE+ adds IQVIA’s Next Best recommendation engine – a daily workflow tool providing AI-driven recommendations for engaging healthcare professionals (HCP) – to its Orchestrated Customer Engagement (OCE) platform, providing enhanced HCP experiences, improved productivity and increased ROI.